European Society of Contraception
|
||||||
|
APRIL 30 – MAY 3 2008 PRAGUE, CZECH REPUBLIC |
||||||
|
|
||||||
|
Results of evaluation of the congress |
||||||
|
Legend: |
5=excellent |
4=good |
3=average |
2=below average |
1=poor |
|
|
|
||||||
|
title lecture |
content | presentation |
| Congress session 1 | ||
| – Mood changes/depression | 4,14 | 3,89 |
| – Weight changes | 4,00 | 4,07 |
| – Bone Mineral Density (BMD) | 4,35 | 4,42 |
| – Breakthrough bleeding | 3,91 | 4,00 |
| – How often and why do women discontinue their
contraceptive method? Results from a French population-based survey |
4,39 | 4,53 |
| – Comparison of patients from high risk population with
vs, without thrombotic events while exposed to hormonal contraception |
4,11 | 3,86 |
| Congress session 2 | ||
| – WHO Global STI
epidemiology update |
4,00 | 3,96 |
| – Testing for STIs in
family planning setting – How to make it simple? |
3,74 | 3,74 |
| – Guidelines for HPV DNA testing – To test or not to
test? |
3,71 | 3,43 |
| – Genital Chlamydial Infection: has
the risk for tubal factor infertility and adverse pregnancy outcome been exaggerated? |
3,92 | 3,93 |
| – To screen or not to
screen…are current guidelines for screening all women for Chlamydia under age 25 being followed in primary care and at family planning clinics? |
3,65 | 3,53 |
| – First sex: an opportunity of a
lifetime for HIV/AIDS prevention |
3,55 | 3,48 |
| Congress
session 3 |
||
| – IUD/IUS in nulliparous women | 3,63 | 3,66 |
| – Management of IUD/IUS in special clinical conditions: emergency
contraception, actinomyces, HIV, dysplasia, cancers… |
3,77 | 3,54 |
| – Non-contraceptive benefits | 4,24 |
4,48 |
| – Long-term use/use beyond recommended time | 3,91 |
3,87 |
| – The Swing IUS: innovative design for intrauterine contraception | 4,12 | 4,17 |
| – Contraception in the postnatal period | 3,50 | 3,53 |
| Congress session 4 | ||
| – The WHO family
planning cornerstones: a living testimony to the power of partnership |
4,61 | 4,23 |
| – Implementation of family planning
guidelines in Europe – adoption and adaptation |
4,38 |
4,61 |
| – Recommended changes in practice | 4,50 | 4,47 |
|
Congress session 5 |
||
| – The challenge of post-abortion contraception |
4,23 |
4,09 |
| – Follow-up after induced abortion: current
practice and evidence |
4,47 | 4,23 |
| – Access to safe
abortion: legal and other obstacles |
3,36 | 3,08 |
| – A
comparison of two dosages of buccal Misoprostol following Mifepristone for early medical abortion |
3,33 | 3,67 |
| – Expanding
options for in-the-mouth Misoprostol administration following Mifepristone in medical abortion |
3,57 | 4,00 |
| Forum 2 | ||
| – Sexual education, sexual health training needs | 4,36 |
4,29 |
| Forum 3 | ||
| – What is required/minimal criteria/what should be examined
before prescribing |
3,88 | 4,06 |
| Keynote lecture 1 | ||
| – HPV
vaccination |
4,21 | 4,13 |
| Keynote lecture 2 | ||
| – Risk of DVT
with new molecules |
4,13 | 4,08 |
| Keynote lecture 3 | ||
| – New
developments in contraception |
4,45 | 4,41 |
| Plenary
session 1 |
||
| – Metabolic benefits | 3,96 | 4,02 |
| – Menorrhagia | 3,93 | 3,98 |
| – Cycle-related symptoms | 4,25 | 4,35 |
| Plenary session 2 | ||
| – Passion, love and relationship | 4,48 | 4,54 |
| – Hormones and sexual behaviour |
4,22 |
4,19 |
| – Sexual problems in the family planning
consultation-what to do |
4,21 | 4,11 |
|
|
